Semantic Scholar uses AI to extract papers important to this topic.
Rolapitant, a selective and long‐acting neurokinin‐1 receptor antagonist, is approved in an oral formulation for the prevention… Expand Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and… Expand BACKGROUND
Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic regimens and can occur for… Expand BACKGROUND
Highly emetogenic chemotherapy induces emesis in almost all patients in the absence of prophylaxis. Guidelines… Expand PurposeRolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist. This study evaluated the safety and efficacy… Expand The incidence of nausea and vomiting after radiotherapy is often underestimated by physicians, though some 50–80% of patients may… Expand The prevention of chemotherapy-induced nausea and vomiting (CINV) has been revolutionized over the past 25 years. Guideline-based… Expand e20690 Background: Rolapitant is a potent, highly selective, competitive and long acting NK-1 receptor antagonist in development… Expand NK1 receptor antagonists have been shown to have a variety of physiological and potential therapeutic effects in animal models… Expand BACKGROUND:Postoperative nausea and vomiting (PONV) are common complications after surgery. Neurokinin-1 (NK1) receptor… Expand